Meihua International Medical Technologies Co., Ltd 6-K, filed Sep 20, 2024
Meihua International Medical Technologies Co., Ltd. (MHUAF)
About this 6-K
Meihua International Medical Technologies Co., Ltd filed this 6-K on September 20, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of September
Commission File Number
(Translation of registrant’s name into English)
88 Tongda Road, Touqiao Town
Guangling District, Yangzhou, 225000
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Explanatory Note
Meihua International Medical Technologies Co., Ltd. (the “Company”) is furnishing its unaudited financial statements for the six months ended June 30, 2024 and incorporating such financial statements into the Company’s registration statements referenced below. The financial statements and notes are attached as Exhibit 99.1 to this report. Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2024 is attached as Exhibit 99.2 to this report. A press release dated September 20, 2024, titled “Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results.” is attached as Exhibit 99.3 to this report.
This Form 6-K is hereby incorporated by reference into the registration statement on Form F-3 (File Number: 333-274194), as amended, and Form F-1 (File Number: 333-276882), as amended, of the Company, and into the prospectus outstanding under the foregoing registration statement, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
1
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Unaudited Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2024 and 2023 | |
| 99.2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | |
| 99.3 | Press Release Titled “Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results” | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Meihua International Medical Technologies Co., Ltd. | ||
| Dated: September 20, 2024 | ||
| By: | /s/ Xin Wang | |
| Name: | Xin Wang | |
| Title: | Chief Executive Officer (Principal Executive Officer) | |
3
Exhibit 99.1
INDEX TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
TABLE OF CONTENTS
F-1
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, 2024 |
December 31, 2023 |
|||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash | $ | $ | ||||||
| Bank acceptance receivables | ||||||||
| Accounts receivable, net | ||||||||
| Accounts receivable-a related party | ||||||||
| Inventories | ||||||||
| Due from a related party-current | ||||||||
| Prepayment and other current assets | ||||||||
| Total current assets | ||||||||
| Property, plant and equipment | ||||||||
| Intangible assets | ||||||||
| Investment | ||||||||
| Deposits to a related party-noncurrent | ||||||||
| Other noncurrent assets | ||||||||
| Operating lease right-of-use asset | ||||||||
| Deferred tax assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and shareholders’ equity | ||||||||
| Liabilities | ||||||||
| Short-term bank borrowings | $ | $ | ||||||
| Convertible debt | - | |||||||
| Accounts payable | ||||||||
| Taxes payable | ||||||||
| Accrued expenses and other current liabilities | ||||||||
| Operating lease liabilities -current | ||||||||
| Total current liabilities | ||||||||
| Operating lease liabilities -noncurrent | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity | ||||||||
| Ordinary share, $ |
||||||||
| Preferred share, $ |
||||||||
| Additional paid-in capital | ||||||||
| Statutory surplus reserves | ||||||||
| Retained earnings | ||||||||
| Accumulated other comprehensive loss | ( |
) | ( |
) | ||||
| Total shareholders’ equity | ||||||||
| Non-controlling interest | ||||||||
| TOTAL EQUITY | ||||||||
| Total liabilities and shareholders’ equity | $ | $ | ||||||
The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.
F-2
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
| For the Six months Ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| Revenues | ||||||||
| Third party sales | $ | $ | ||||||
| Related party sales | ||||||||
| Total revenues | ||||||||
| Cost of revenues | ||||||||
| Gross profit | ||||||||
| Operating expenses | ||||||||
| Selling | ||||||||
| General and administrative | ||||||||
| Research and development | ||||||||
| Provision for credit loss | ||||||||
| Total operating expenses | ||||||||
| Income from operations | ||||||||
| Other (income) expense: | ||||||||
| Change in fair value in convertible debt | ||||||||
| Interest expense | ||||||||
| Interest income | ( | ) | ( | ) | ||||
| Currency exchange (gain) loss | ( | ) | ||||||
| Other (income) expense, net | ( | ) | ||||||
| Total other expenses | ||||||||
| Income before income tax provision | ||||||||
| Income taxes expense | ||||||||
| Net income | $ | |||||||
| Net loss attributable to non-controlling interests | ( | ) | ( | ) | ||||
| Net income attributable to shareholders | ||||||||
| Foreign currency translation adjustment –loss | ( | ) | ( | ) | ||||
| Comprehensive income | $ | $ | ||||||
| Comprehensive loss attributable to non-controlling interests | ( | ) | ( | ) | ||||
| Comprehensive income attributable to shareholders | ||||||||
| Weighted average number of ordinary shares - basic | ||||||||
| Weighted average number of ordinary shares - diluted | ||||||||
| Basic net income per ordinary share | $ | $ | ||||||
| Diluted net income per ordinary share | $ | $ | ||||||
The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.
F-3
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| Ordinary shares | Ordinary shares amount | Additional paid-in capital | Statutory surplus reserves | Retained earnings | Accumulated other comprehensive income (loss) | Non- controlling interests | Total Equity | |||||||||||||||||||||||||
| Balance as of December 31, 2022 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
| Net income | - | ( | ) | |||||||||||||||||||||||||||||
| Currency translation adjustment | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance as of June 30, 2023 | ( | ) | ||||||||||||||||||||||||||||||
| Balance as of December 31, 2023 | ( | ) | ||||||||||||||||||||||||||||||
| Conversion of convertible debt | ||||||||||||||||||||||||||||||||
| Warrants | - | |||||||||||||||||||||||||||||||
| Net income | - | ( | ) | |||||||||||||||||||||||||||||
| Disposal of shareholders’ interest in a subsidiary | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Appropriation of statutory reserve | - | ( | ) | |||||||||||||||||||||||||||||
| Currency translation adjustment | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance as of June 30, 2024 | ( | ) | ||||||||||||||||||||||||||||||
The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.
F-4
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For The Six Months Ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| Cash Flows from operating activities: | ||||||||
| Net income | $ | $ | ||||||
| Adjustments reconcile net income to net cash provided by (used in) operating activities: | ||||||||
| Depreciation | ||||||||
| Amortization | ||||||||
| Net loss from disposal of property, plant and equipment | ||||||||
| Provision for credit loss | ||||||||
| Deferred tax benefit | ( | ) | ||||||
| Currency exchange (gain) loss | ( | ) | ||||||
| (Gain) loss from equity method investments | ( | ) | ||||||
| Gain from cost method investments | ( | ) | ||||||
| Gain from disposal of equity interest in a subsidiary | ( | ) | ||||||
| Change in fair value in convertible debt | ||||||||
| Amortization of operating lease right-of-use assets | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Bank acceptance receivables | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Accounts receivable-related party | ( | ) | ||||||
| Inventories | ( | ) | ||||||
| Prepayments and other assets | ( | ) | ||||||
| Accounts payable | ( | ) | ||||||
| Accrued expenses and other current liabilities | ( | ) | ||||||
| Advance from customers | ( | ) | ||||||
| Taxes payable | ||||||||
| Operating leases liabilities | ( | ) | ||||||
| Net cash provided by (used in) operating activities | ( | ) | ||||||
| Cash flows from investing activities: | ||||||||
| Purchases of property, plant and equipment | ( | ) | ( | ) | ||||
| Advance to a related party | ( | ) | ||||||
| Additions to intangible assets | ( | ) | ||||||
| Proceeds from disposal of property, plant and equipment | ||||||||
| Proceeds from disposal of long-term investment | ||||||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from convertible debt | ||||||||
| Proceeds from short-term bank borrowings | ||||||||
| Repayments of short-term bank borrowings | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Effect of foreign exchange rate changes | ( | ) | ( | ) | ||||
| Net increase (decrease) in cash | ( | ) | ||||||
| Cash, beginning of the period | ||||||||
| Cash, end of the period | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: | ||||||||
| Cash paid for income tax | $ | $ | ||||||
| Cash paid for interest | $ | $ | ||||||
The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.
F-5
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Organization and principal activities
Principal Activities:
Meihua International Medical Technologies Co., Ltd. (“Meihua” or the “Company”) was incorporated on November 10, 2020 in the Cayman Islands. Meihua is a holding company with no operations. Meihua produces and sells medical consumables through its subsidiaries located in People’s Republic of China (“PRC” or “China”).
| Entity Name | Registered Location | Percentage of ownership | Date of incorporation | Principal activities | ||||
| 康复国际医疗有限公司 Kang Fu International Medical Co., Limited (“Kang Fu”) | ||||||||
| 扬州华达医疗器械有限公司 Yangzhou Huada Medical Equipment Co., Ltd. (“Huada”) | ||||||||
| 江苏亚达科技集团有限公司 Jiangsu Yada Technology Group Co., Ltd. (“Yada”) | ||||||||
| 江苏华东医疗器械实业有限公司 Jiangsu Huadong Medical Device Industry Co., Ltd. (“Huadong”) | ||||||||
| 海南瑞营科技有限公司 Hainan Ruiying Technology Co., Ltd. (“Hainan Ruiying”) |
Kang Fu was incorporated on October 13, 2015 with
a registered capital of HKD
Huada is a subsidiary wholly owned by Kang Fu and established in Yangzhou,
China on December 24, 2001 with a registered capital of $
Yada is a subsidiary wholly owned by Huada and
was established in Yangzhou, China on December 5, 1991 with a registered capital of RMB
Huadong is a subsidiary wholly owned by Yada
and was established in Yangzhou, China on November 18, 2000 with a registered capital of RMB
Those three subsidiaries primarily manufacture and sell Class I, II and III disposable medical devices under the Company’s own brands, and distribute Class I, II and III disposable medical devices sourced from other manufacturers to our domestic and overseas customers.
Hainan Ruiying is a subsidiary
F-6
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”). The interim results of operations are not necessarily indicative of results to be expected for any other interim period or for a full year. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of its financial position and operating results have been included. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the related notes thereto for the fiscal years ended December 31, 2023 and 2022.
Use of Estimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and related notes.
The most significant estimates and judgments include allowance for credit losses, the valuation of inventory, useful life of property, plant and equipment and income taxes related to realization of deferred tax assets and uncertain tax position. Actual amounts could differ from those estimates.
Non-controlling interests
Non-controlling interest represents the portion of the net assets of subsidiaries attributable to interests that are not owned or controlled by the Company. The non-controlling interest is presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interest’s operating results are presented on the face of the consolidated statements of income and comprehensive income as an allocation of the total income for the period between non-controlling shareholders and the shareholders of the Company. As of June 30, 2024, non-controlling interests amounted to $, representing non-controlling shareholders’ proportionate share of equity interests in Hainan Ruiying, which has not begun operations.
F-7
Functional Currency and Foreign Currency Translation
The Company’s reporting currency is the United States dollar (“US$”). The Company’s operations are principally conducted through the PRC subsidiaries where the local currency is the functional currency. Therefore, the functional currency of Kang Fu is Hong Kong dollar and the functional currency of other subsidiaries is Renminbi (“RMB”).
Transactions denominated in currencies other than the functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Monetary assets and liabilities denominated in currencies other than the applicable functional currency are translated into the functional currency at the prevailing rates of exchange at the balance sheet date. The resulting exchange differences are reported in the consolidated statements of income and comprehensive income.
The assets and liabilities of the Company are translated at the exchange
spot rate at the balance sheet date, shareholders’ equity is translated at the historical rates and the revenues and
expenses are translated at the average exchange rates for the periods, except that the exchange rate used for translation from Hong Kong
dollar to US$ was
June 30, 2024 | December 31, 2023 | June 30, 2023 | ||||
| Period-end spot rate | US$1=RMB | US$1=RMB | US$1=RMB | |||
| Average rate | US$1=RMB | US$1=RMB | US$1=RMB |
Certain Risks and Concentration
The Company’s financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and receivables. As of June 30, 2024 and December 31, 2023 substantially all the Company’s cash was held in major financial institutions located in Hong Kong and mainland China, which institutions management considers to be of high credit quality.
For the six months ended June 30, 2024, one customer
accounted for approximately
As of June 30, 2024, one customer accounted for
approximately
For the six months ended June 30, 2024, one supplier
accounted for approximately
Fair Value Measurement
Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability.
F-8
The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
| Level 1: | Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. | |
| Level 2: | Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. | |
| Level 3: | Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. |
The Company’s financial instruments include cash, accounts receivable, bank acceptance receivables, due from related parties, accounts payable, other liabilities and accrued expenses and short-term bank borrowings. The carrying amounts approximate their fair values due to their short maturities as of June 30, 2024 and December 31, 2023.
The Company elected the fair value option to account for its convertible loans. The Company engaged an independent valuation firm to perform the valuation. The convertible loans are classified as level 3 instruments as the valuation was determined based on unobservable inputs which are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. Significant estimates used in developing the fair value of the convertible loans include time to maturity, historical volatility of the Company’s share prices, risk-free interest rate and discount rate. Refer to Note 8 for additional information.
As the inputs used in developing the fair value for level 3 instruments are unobservable, and require significant management estimation, a change in these inputs could result in a significant change in the fair value measurement.
June 30, 2024 | ||||
| Opening balance | $ | |||
| New convertible loans issued | ||||
| Loss on change in fair value of convertible loan | ||||
| Conversion of convertible loans | ( | ) | ||
| Total | $ | |||
Accounts Receivable and Allowance for Credit Losses
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which requires the Company to measure and recognize expected credit losses for financial assets held and not accounted for at fair value through net income. The Company adopted this guidance effective January 1, 2020. ASC 326 introduces an approach based on expected losses to estimate the allowance for credit losses, which replaces the previous incurred loss impairment model. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. Accounts receivable are recognized and carried at original invoiced amount less an estimated allowance for credit losses. The Company estimates the allowance for credit losses based on an analysis of the aging of accounts receivable, assessment of collectability, including any known or anticipated economic conditions, customer-specific circumstances, recent payment history and other relevant factors.
The Company’s provision for credit losses
related to accounts receivable were $
F-9
Inventories
Inventories are valued using the lower of cost or net realizable value. Cost is principally determined using the weighted-average method. Manufactured inventories included cost of materials, labor and overhead expenses. The Company records adjustments to inventory for excess quantities, obsolescence, or impairment, when appropriate, to reflect inventory at net realizable value. These adjustments are based upon a combination of factors including current sales volume, market conditions, lower of cost or market analysis and expected realizable value of the inventory.
There were no write-downs recognized on inventories as of June 30, 2024 and December 31, 2023.
Intangible Assets
Intangible assets are non-monetary assets without
physical substance. These items are initially measured at cost and subsequently carried at cost less any accumulated amortization and
impairment losses. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives.
| Category | Useful lives | |
| Land use rights | ||
| Patent | ||
| Trademark |
Impairment of Long-Lived Assets
The Company accounts for impairment of long-lived assets in accordance with Accounting Standards Codification (“ASC”) 360, Property, Plant and Equipment. (“ASC 360”). Long-lived assets consist primarily of property, plant and equipment, and intangible assets. In accordance with ASC 360, the Company evaluates the carrying value of long-lived assets when it determines a triggering event has occurred, or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When indicators exist, recoverability of assets is measured by a comparison of the carrying value of the asset group to the estimated undiscounted future net cash flows expected to be generated by the asset. Examples of such triggering events include a significant disposal of a portion of such assets, and adverse change in the market involving the business employing the related assets. If such assets are determined not to be recoverable, the Company performs an analysis of the fair value of the asset group and will recognize an impairment loss when the fair value is less than the carrying amounts of such assets. The fair value, based on reasonable and supportable assumptions and projections, require subjective judgments. Depending on the assumptions and estimates used, the appraised fair value projected in the evaluation of long-lived assets can vary within a range of outcomes. The Company considers the likelihood of possible outcomes in determining the best estimate for the fair value of the assets. The Company did not record any impairment charges as of June 30, 2024 and December 31, 2023. There can be no assurance that future events will not have impact on company revenue or financial position which could result in impairment in the future.
F-10
Investment
In accordance with Financial Accounting Standards Board (“FASB”) ASC 321, “Investment-Equity Securities,” the Company accounts for non-marketable securities on a prospective basis. Equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient are eligible for the measurement alternative.
On March 3, 2011, Yada invested in Yangzhou Juyuan
Guarantee Co., Ltd (“Juyuan”) and obtained a
Investments in entities in which the Company can exercise significant influence but does not own a majority equity interest or control are accounted for using the equity method of accounting in accordance with ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Under the equity method, the Company initially records its investment at cost and the difference between the cost of the equity investee and the amount of the underlying equity in the net assets of the equity investee is accounted for as if the investee were a consolidated subsidiary. The share of earnings or losses of the investee are recognized in the consolidated statements of comprehensive loss. Equity method adjustments include the Company’s proportionate share of investee income or loss, adjustments to recognize certain differences between the Company’s carrying value and its equity in net assets of the investee at the date of investment, impairments, and other adjustments required by the equity method. The Company assesses its equity investment for other-than-temporary impairment by considering factors as well as all relevant and available information including, but not limited to, current economic and market conditions, the operating performance of the investees including current earnings trends, the general market conditions in the investee’s industry or geographic area, factors related to the investee’s ability to remain in business, such as the investee’s liquidity, debt ratios, and cash burn rate and other company-specific information.
Investments in equity securities without readily determinable fair values are measured at cost minus impairment adjusted by observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are measured at fair value on a nonrecurring basis when there are events or changes in circumstances that may have a significant adverse effect. An impairment loss is recognized in the consolidated statements of comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. Prior to the adoption of ASU 2016-01 on January 1, 2019, these investments were accounted for using the cost method of accounting, measured at cost less other-than-temporary impairment.
On December 1, 2022, Huadong invested RMB
On February 26, 2024, the Company
transferred
After the transaction, the Company accounted for
the investments using the equity method, because the Company has significant influence but does not own a majority equity interest or
otherwise exercise control over the equity investee. Under the equity method, the Company adjusts the carrying amount of the investment
and recognizes investment income or loss for its share of the earnings or loss in the investee after the date of investment. When the
Company’s share of losses in the equity investee equals or exceeds its interest in the equity investee, the Company does not recognize
further losses unless the Company has incurred obligations or made payments or guarantees on behalf of the equity investee. For the six
months ended June 30, 2024 and 2023, the investment gain from Guoxie was $
F-11
The Company continually reviews its investments in equity investees to determine whether a decline in fair value below the carrying value is other-than-temporary. The primary factors the Company considers in its determination include the financial condition, operating performance and the prospects of the equity investee; other company specific information such as recent financing rounds; the geographic region, market and industry in which the equity investee operates; and the length of time that the fair value of the investment is below its carrying value. If the decline in fair value is deemed to be other-than-temporary, the carrying value of the equity investee is written down to fair value.
For the for the six months ended June 30, 2024 and 2023, no impairment indicators were identified and no loss related to revaluation of its investment in the private company was recorded.
Related Parties
Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management, and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all significant related party transactions.
Revenue Recognition
Effective January 1, 2018, the Company adopted ASC Topic 606 using the modified retrospective adoption method. Based on the requirements of ASC Topic 606, revenue is recognized when control of the promised goods or services is transferred to the customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. The Company primarily sells its products to hospitals and medical equipment companies. Revenue is recognized when the following 5-step revenue recognition criteria are met:
| 1) | Identify the contract with a customer |
| 2) | Identify the performance obligations in the contract |
| 3) | Determine the transaction price |
| 4) | Allocate the transaction price |
| 5) | Recognize revenue when or as the entity satisfies a performance obligation |
Revenue from product sales is recognized at the point in time control of the products is transferred, generally upon customer receipt based upon the standard contract terms. Shipping and handling activities are considered to be fulfillment activities rather than promised services and are not, therefore, considered to be separate performance obligations. The Company’s sales terms provide no right of return outside of a standard quality policy and returns are generally not significant. Payment terms for product sales are generally set at 90 to 180 days after the consideration becomes due and payable.
F-12
Revenue Disaggregation
Type of Goods
| For The Six Months Ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| US$ | US$ | |||||||
| Self-Manufactured Products | ||||||||
| Resales of Sourced Disposable Medical Devices from Third Party Manufacturers | ||||||||
| Total Revenue | ||||||||
| For The Six Months Ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| US$ | US$ | |||||||
| Direct sales | ||||||||
| Distributors | ||||||||
| Total Revenue | ||||||||
Earnings per Ordinary Share
Earnings (loss) per ordinary share is calculated in accordance with ASC 260, Earnings per Share. Basic earnings (loss) per ordinary share is computed by dividing the net income (loss) attributable to shareholders of the Company by the weighted average number of ordinary shares outstanding during the year. Diluted earnings (loss) per share is computed using the weighted average number of ordinary shares and potential ordinary shares outstanding during the period. Potential ordinary shares include ordinary shares issuable upon the exercise of outstanding share options and vesting of restricted share units by using the treasury stock method and ordinary shares issuable upon the conversion of convertible instruments using the if-converted method. Potential ordinary shares are not included in the denominator of the diluted net (loss)/earnings per share calculation when inclusion of such shares would be anti-dilutive.
Comprehensive Income (Loss)
ASC 220, Comprehensive Income (“ASC 220”) establishes rules for reporting and display of comprehensive income and its components. ASC 220 requires that unrealized gains and losses on the Company’s foreign currency translation adjustments be included in comprehensive income (loss).
Advertising Costs
The Company’s advertising costs are expensed
as incurred. Advertising expenses are included in selling expenses in the accompanying consolidated statements of income and comprehensive
income. Advertising expenses were $
Research and Development Costs
Research and development expenses are expensed
as incurred. Research and development expenses were $
F-13
Income Tax
Current income taxes are provided on the basis of net profit for financial reporting purposes, adjusted for income and expense items which are not assessable or deductible for income tax purposes, in accordance with the regulations of the relevant tax jurisdictions.
Deferred income taxes are recognized for temporary differences between the tax basis of assets and liabilities and their reported amounts in the consolidated financial statements, net operating loss carry forwards and credits. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided in accordance with the laws of the relevant taxing authorities. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in which temporary differences are expected to be reversed or settled. The effect on deferred tax assets and liabilities of changes in tax rates is recognized in the statement of comprehensive income in the period of the enactment of the change.
The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carryforwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.
The Company recognizes a tax benefit associated
with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination
by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently
measures the tax benefit as the largest amount that the Company judges to have a greater than
Segment Reporting
FASB 280, “Segment Reporting,” establishes
standards for reporting information about operating segments on a basis consistent with the Company’s internal organizational structure
as well as information of the Company’s business segments, geographical areas, segments and major customers. The Company uses the
“management approach” in determining reportable operating segments. The management approach considers the internal organization
and reporting used by the Company’s chief operating decision maker for making operating decisions and assessing performance as
the source for determining the Company’s reportable segments. The chief operating decision maker is the Company’s president
and Chief Executive Officer (“CEO”). Management, including the chief operating decision maker, reviews operating results
of different products at revenue level with no allocation of operating costs. Consequently, based on management’s assessment, the
Company has determined that it has only
F-14
| June 30, 2024 | June 30, 2023 | |||||||||||||||||||||||
| US$ | US$ | |||||||||||||||||||||||
| Category | Produced | Purchased | Total | Produced | Purchased | Total | ||||||||||||||||||
| Class I | ||||||||||||||||||||||||
| Class II | ||||||||||||||||||||||||
| Class III | ||||||||||||||||||||||||
| Others | ||||||||||||||||||||||||
| Total | ||||||||||||||||||||||||
Class I, II, and III medical devices are defined by the National Medical Products Administration of China according to their risk levels under the Regulation on the Supervision and Administration of Medical Devices (2021 Revision), Article 6 as follows:
| ● | “Class I Medical Devices” means medical devices with low risks, whose safety and effectiveness can be ensured through routine administration. |
| ● | “Class II Medical Devices” means medical devices with moderate risks, which shall be strictly controlled and administered to ensure their safety and effectiveness. |
| ● | “Class III Medical Devices” means medical devices with relatively high risks, which shall be strictly controlled and administered through special measures to ensure their safety and effectiveness. |
June 30, 2024 | June 30, 2023 | |||||||||
| Category | Products | US$ | US$ | |||||||
| Class I | Eye drops bottle | |||||||||
| Oral medicine bottle | ||||||||||
| Anal bag | ||||||||||
| Other Class I | ||||||||||
| Subtotal-Class I | ||||||||||
| Class II | Masks | |||||||||
| Identification tape | ||||||||||
| Disposable medical brush | ||||||||||
| Gynecological inspection kits | ||||||||||
| Surgical kit | ||||||||||
| Medical brush | ||||||||||
| Medical kit | ||||||||||
| Other Class II | ||||||||||
| Subtotal-Class II | ||||||||||
| Class III | Electronic pump | |||||||||
| Anesthesia puncture kit | ||||||||||
| Disposable infusion pump | ||||||||||
| Infusion pump | ||||||||||
| Electronic infusion pump | ||||||||||
| Laparoscopic trocar | ||||||||||
| Other Class III | ||||||||||
| Subtotal-Class III | ||||||||||
| Others | ||||||||||
| Total | ||||||||||
For the six months ended June 30, 2024, and 2023,
revenues and assets within the PRC contributed to more than
F-15
Recent Accounting Pronouncements
In June 2022, the FASB issued ASU 2022-03 Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. The update clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The update also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The update also requires certain additional disclosures for equity securities subject to contractual sale restrictions. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. As an emerging growth company, the standard is effective for the Company for the year ended December 31, 2025. The Company is in the process of evaluating the impact of the new guidance on its consolidated financial statements.
In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). This ASU requires that public business entities must annually “(1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate).” A public entity should apply the amendments in ASU 2023-09 prospectively to all annual periods beginning after December 15, 2024. The Company is currently evaluating these new disclosure requirements and does not expect the adoption to have a material impact.
On November 27, 2023, the FASB issued ASU 2023-07. The amendments improve reportable segment disclosure requirements. Main provisions include: (1) significant segment expenses—public entities are required to disclose significant segment expenses by reportable segment if they are regularly provided to the CODM and included in each reported measure of segment profit or loss; (2) other segment items—public entities are required to disclose other segment items by reportable segment. Such a disclosure would constitute the difference between reported segment revenues less the significant segment expenses (disclosed) less reported segment profit or loss; (3) multiple measures of a segment’s profit or loss—public entities may disclose more than one measure of segment profit or loss used by the CODM, provided that at least one of the reported measures includes the segment profit or loss measure that is most consistent with GAAP measurement principles; (4) CODM-related disclosures—disclosure of the CODM’s title and position is required on an annual basis, as well as an explanation of how the CODM uses the reported measure(s) and other disclosures. (5) entities with a single reportable segment—public entities must apply all of the ASU’s disclosure requirements, as well as all existing segment disclosure and reconciliation requirements in ASC 280; (6) recasting of prior-period segment information to conform to current-period segment information—recasting is required if segment information regularly provided to the CODM is changed in a manner that causes the identification of significant segment expenses to change. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023. The adoption of this guidance did not have a material impact on the Company’s unaudited condensed consolidated financial statements.
On March 21, 2024, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2024-01 (“ASU 2024-01”), which clarifies how an entity determines whether a profits interest or similar award is (1) within the scope of ASC 718 or (2) not a share-based payment arrangement and therefore within the scope of other guidance. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. ASU 2024-01 is effective for public business entities for annual periods beginning after December 15, 2024, including interim periods within those periods. The Company is currently evaluating the impact of the adoption of ASU 2024-01 on its consolidated financial statements.
The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company’s consolidated balance sheets, statements of income and statements of cash flows.
F-16
3. Accounts receivable, net
| June 30, 2024 | December 31, 2023 | |||||||
| Accounts receivable | $ | $ | ||||||
| Less: allowances for credit losses | ( | ) | ( | ) | ||||
| Total accounts receivable, net | ||||||||
| Less: accounts receivable, net, related parties | ( | ) | ( | ) | ||||
| Accounts receivable from third parties, net | $ | $ | ||||||
For the six months ended June 30, 2024, and 2023,
provision for credit losses amounted to $
| For the six months ended June 30, 2024 |
For the year ended December 31, 2023 |
|||||||
| Beginning balance | $ | $ | ||||||
| Bad debt provision | ||||||||
| Foreign exchange translation | ( |
) | ( |
) | ||||
| Ending balance | $ | $ | ||||||
4. Inventories
| June 30, 2024 | December 31, 2023 | |||||||
| US$ | US$ | |||||||
| Raw material | ||||||||
| Work-in-process | ||||||||
| Finished goods | ||||||||
| Low-value consumables | ||||||||
| Total | ||||||||
For the six months ended June 30, 2024 and 2023, there were writes-down of inventories.
5. Intangible Assets
| June 30, 2024 | December 31, 2023 | |||||||
| US$ | US$ | |||||||
| Land use rights* | ||||||||
| Patents | ||||||||
| Software | ||||||||
| Trademarks | ||||||||
| Total | ||||||||
| Less: accumulated amortization | ( | ) | ( | ) | ||||
| Intangible assets, net | ||||||||
| * |
F-17
Amortization expense was $
| For the six months ending December 31, | ||||
| 2024 | $ | |||
| For the years ending December 31, | ||||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| Thereafter | ||||
| $ | ||||
6. Investment
On March 3, 2011, Yada invested RMB
On December 1, 2022, Huadong invested RMB
On February 26, 2024, the Company transferred
its
For the six months ended June 30, 2024 and 2023, no impairment indicators were identified and no loss related to revaluation of its investment in the private company was recorded.
F-18
7. Bank Borrowings
Bank borrowings are working capital loans from
banks in China.
| Lender | Company | Rate | Issuance Date | Expiration Date | Amount- RMB | Amount- US$ | ||||||||||||
| Jiangsu Yangzhou Rural Commercial Bank | Huadong | % | ||||||||||||||||
| Bank of China | Huadong | % | ||||||||||||||||
| Minsheng Bank | Huadong | % | ||||||||||||||||
| Bank of Communications | Huadong | % | ||||||||||||||||
| Bank of Jiangsu | Huadong | % | ||||||||||||||||
| Industrial and Commercial Bank of China | Yada | % | ||||||||||||||||
| Agricultural Bank of China | Yada | % | ||||||||||||||||
| Total | ||||||||||||||||||
| Lender | Company | Rate | Issuance Date | Expiration Date | Amount- RMB | Amount- US$ | ||||||||||||
| Jiangsu Yangzhou Rural Commercial Bank | Huadong | % | ||||||||||||||||
| Bank of China | Huadong | % | ||||||||||||||||
| Bank of Communications | Huadong | % | ||||||||||||||||
| Bank of Communications | Huadong | % | ||||||||||||||||
| Agricultural Bank of China | Huadong | % | ||||||||||||||||
| Industrial and Commercial Bank of China | Yada | % | ||||||||||||||||
| Agricultural Bank of China | Yada | % | ||||||||||||||||
| Total | ||||||||||||||||||
Interest expense was $
The Company’s short-term bank borrowings are pledged by the Company’s assets and guaranteed by the Company’s major shareholders Yongjun Liu, Yin Liu, and its subsidiary Yada.
| June 30, 2024 | December 31, 2023 | |||||||
| US$ | US$ | |||||||
| Buildings, net | ||||||||
| Land use right, net | ||||||||
| Total | ||||||||
F-19
8. Convertible loans
On December 27, 2023, the Company entered into
a securities purchase agreement (the “SPA”) with certain institutional investors (the “Investors”), pursuant
to which the Company agreed to issue, from time to time, up to $ in the Company’s securities (the “Offering”),
consisting of convertible notes, issuable at a
The First Closing occurred on January 2, 2024. Gross proceeds amounted
to approximately $
Based
on the valuation report performed by an independent valuation firm, the fair value of the convertible notes upon issuance was determined
to be of $
| For the six months ended June 30, 2024 | ||||
| Time to maturity | ||||
| Historical volatility of the company’s share prices | ||||
| Risk-free interest rate | ||||
| Discount rate |
The
convertible debt was partially converted into
For the six months ended June 30, 2024,
due to a change in fair value of the convertible loans, the Company recognized unrealized loss of $
F-20
9. Taxes Payable
| June 30, 2024 | December 31, 2023 | |||||||
| US$ | US$ | |||||||
| VAT payable | ||||||||
| Income tax payable | ||||||||
| Other tax payable | ||||||||
| Total | ||||||||
10. Income Taxes
Cayman Islands
Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gain. Additionally, upon payments of dividends to the shareholders, no Cayman Islands withholding tax is imposed.
Hong Kong
Under the current Hong Kong Inland Revenue Ordinance,
the Company’s Hong Kong subsidiary, Kang Fu, is subject to
PRC
| June 30, 2024 |
June 30, 2023 |
|||||||
| US$ | US$ | |||||||
| Provisions for current income tax | ||||||||
| Provisions for deferred income tax | ( |
) | ||||||
| Total | ||||||||
June 30, 2024 | June 30, 2023 | |||||||
| US$ | US$ | |||||||
| Income before income tax provision | ||||||||
| Tax at the PRC statutory tax rates | ||||||||
| Preferential tax rates | ( | ) | ( | ) | ||||
| Change in valuation allowance | ||||||||
| Tax effect of non-deductible expenses | ||||||||
| Tax effect of R&D expenses additional deduction* | ( | ) | ( | ) | ||||
| Income tax expense | ||||||||
| * |
F-21
Under the Enterprise Income Tax Law (“EIT
Law”), Foreign Investment Enterprises (“FIEs”) and domestic companies are subject to Enterprise Income Tax (“EIT”)
at a uniform rate of
Huadong was granted a High and New Technology
Enterprise (“HNTE”) certificate and received a preferential tax rate of
The EIT Law also provides that an enterprise
established under the laws of a foreign country or region but whose “de facto management body” is located in the PRC be treated
as a resident enterprise for PRC tax purposes and consequently be subject to the PRC income tax at the rate of
The EIT Law also imposes a withholding income
tax on dividends distributed by a FIE to its immediate holding company outside of the PRC. Kang Fu, which is the parent of Huada, Yada
and Huadong, is therefore subject to a maximum withholding tax of
Uncertain tax positions
The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measures the unrecognized benefits associated with the tax positions. As of June 30, 2024 and December 31, 2023, the Company did not have any significant unrecognized uncertain tax positions.
11. Shareholders’ Equity
Ordinary Shares
As of June 30, 2024 and December 31, 2023,
F-22
Conversion of convertible loans
On
January 24, 2024, the Company issued
Subsequently, on July 31, 2024, the Company issued
Warrants
As of June 30, 2024, there were
As of issue date (Jan 2, 2024) | ||||
| Share price | $ | |||
| Exercise price | $ | |||
| Interest rate | % | |||
| Time to maturity | ||||
| Volatility | % | |||
| Number of warrants | Weighted average exercise price per share | Weighted average life | Expiration dates | |||||||||
| US$ per share | Years | |||||||||||
| Balance of warrants outstanding as of December 31, 2023 | ||||||||||||
| - warrants issued in connection with the convertible loans | ||||||||||||
| Balance of warrants outstanding and exercisable as of June 30, 2024 | | |||||||||||
12. Statutory Surplus Reserves and Restricted Net Assets
Pursuant to laws applicable to entities incorporated
in the PRC, the Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the
discretionary surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of
the PRC (“PRC GAAP”). Appropriations to the statutory surplus reserve are required to be at least
As a result of these PRC laws and regulations
and the requirement that distributions by PRC entities can only be paid out of distributable profits computed in accordance with PRC
GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Company. Amounts restricted include paid-in
capital and the statutory reserves of the Company’s PRC subsidiaries. The aggregate amounts of capital and statutory reserves restricted
which represented the amount of net assets of the relevant subsidiaries in the Company not available for distribution was $
Under PRC laws and regulations, statutory surplus reserves are restricted to set-off against losses, expansion of production and operation and increasing registered capital of the respective company and are not distributable other than upon liquidation. The reserves are not allowed to be transferred to the Company in terms of cash dividends, loans or advances, nor allowed for distribution except under liquidation.
F-23
13. Related Party Transactions and Balances
(1)
| Name of related parties | Relationship with the Company | |
(2)
| Name of related party | June 30, 2024 | December 31, 2023 | ||||||
| Yangzhou Meihua Import and Export Co., Ltd. | $ | $ | ||||||
As of June 30, 2024, the Company sold manufactured
products to Yangzhou Meihua Import and Export Co., Ltd. Subsequently, the Company collected $
(3)
| Name of related party | June 30, 2024 | December 31, 2023 | ||||||
| Li Jun | $ | $ | ||||||
| Hainan Guoxie | ||||||||
| Total | $ | $ | ||||||
During the six months ended June 30, 2024, the
Company advanced $
(4)
| Name of related party | June 30, 2024 | December 31, 2023 | ||||||
| Liu Fang | $ | $ | ||||||
On January 19, 2023, Huadong signed a letter
of intent with Ms. Liu Fang to purchase
(5) Related Party Sales
| For the Six Months ended June 30, | ||||||||
| Name of related party | 2024 | 2023 | ||||||
| Yangzhou Meihua Import and Export Co., Ltd. | $ | $ | ||||||
14. Subsequent Events
The Company has evaluated the impact of events that have occurred subsequent to June 30, 2024 through the issuance date of the unaudited condensed consolidated financial statements and concluded that no subsequent events have occurred that would require recognition in the unaudited condensed consolidated financial statements or disclosure in the notes to the unaudited condensed consolidated financial statements.
F-24
Exhibit 99.2
Management’s discussion and analysis of the financial condition and results of operations of Meihua International Medical Technologies Co., Ltd. (the “Company,” “we,” “our,” or “us”) for the six months ended June 30, 2024 is set forth below:
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this filing. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This discussion contains forward-looking statements. All statements contained in this discussion other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the “Risk Factors” section of our annual report and registration statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
A. Operating Results
Business Overview
The Company, through its operating subsidiaries, is mainly engaged in the manufacture, research and development and sales of Class I, II and III medical devices. It has a history of more than 30 years and has a sound product category, with more than 800 domestic products and more than 120 export products. The main product lines include disposable infusion pumps, anesthesia puncture kits, electronic pumps, full anesthesia kits, urethral catheterization kits, gynecological examination kits, endotracheal intubation, dressing application and various tubes. It is the leading enterprise in China’s medical consumables industry. The Company has received qualification to manufacture and produce China’s first, second and third type of medical device consumables and, at the same time, the Company has acquired FDA registration and the European Union’s CE certification. Relevant permissions have been obtained in major sales markets to meet local regulatory requirements.
The Company’s distribution network covers major global markets. Internationally, the Company mainly exports medical devices through exporting distributors. Up to now, the Company has 354 exporting distributors responsible for distributing its products to end users in Europe, North America, Asia, South America, Africa and Oceania. In the Chinese market, the Company sells products under its own brand to customers all over the country. The Company’ product permeation for mainland China has reached major medical institutions and pharmacies through some 4,033 distributors. At the same time, the Company has established a cooperative network with more than 540 hospitals through its own direct sales channels.
Revenues decreased by approximately $2.85 million, or approximately 5.9%, to $45.34 million for the six months ended June 30, 2024 from approximately $48.19 million for the six months ended June 30, 2023. The decrease was mainly due to a decline in demand for customer orders, which we believe occurred because of the stalling recovery of China’s economy.
Net income decreased by approximately $2.32 million, or approximately 33.0%, to $4.71 million for the six months ended June 30, 2024 from approximately $7.03 million for the six months ended June 30, 2023. The decrease was mainly due to a decrease in gross profit and increase in expected credit loss.
Recent Developments
On June 26, 2024, the board of directors (the “Board”) of the Company approved and authorized the Company’s proposal to adopt a share repurchase plan of up to $3 million of the Company’s outstanding ordinary shares (the “Share Repurchase Plan”). Under the Share Repurchase Plan, the Company’s management is authorized to purchase ordinary shares from time to time through open market purchases or privately negotiated transactions at prevailing prices as permitted by securities laws and other legal requirements, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company’s insider trading policy, and subject to market conditions and other factors.
Results of Operations
The following table sets forth a summary of our unaudited consolidated results of operations for the periods presented. This information should be read together with our unaudited condensed consolidated financial statements and related notes included in this filing. The results of operations in any period are not necessarily indicative of our future trends.
(Amounts expressed in U.S. dollars, except share data and per share data, or otherwise noted)
For the six months ended June 30, 2024 and 2023 (Unaudited)
For the Six Months Ended (Unaudited) | ||||||||
| 2024 | 2023 | |||||||
| Revenues | ||||||||
| Third party sales | $ | 45,035,893 | $ | 48,178,325 | ||||
| Related party sales | 307,805 | 11,751 | ||||||
| Total revenues | 45,343,698 | 48,190,076 | ||||||
| Cost of revenues | 30,158,297 | 31,019,347 | ||||||
| Gross profit | 15,185,401 | 17,170,729 | ||||||
| Operating expenses | ||||||||
| Selling | 3,199,538 | 3,161,070 | ||||||
| General and administrative | 3,502,639 | 3,452,610 | ||||||
| Research and development | 1,459,945 | 1,460,376 | ||||||
| Provision for credit loss | 1,131,267 | - | ||||||
| Total operating expenses | 9,293,389 | 8,074,056 | ||||||
| Income from operations | 5,892,012 | 9,096,673 | ||||||
| Other (income) expense: | ||||||||
| Change in fair value in convertible debt | 514,862 | - | ||||||
| Interest expense | 129,292 | 128,973 | ||||||
| Interest income | (292,670 | ) | (361,532 | ) | ||||
| Currency exchange (gain) loss | (327,531 | ) | 119,193 | |||||
| Other (income) expense, net | (17,289 | ) | 114,298 | |||||
| Total other expenses | 6,664 | 932 | ||||||
| Income before income tax provision | 5,885,348 | 9,095,741 | ||||||
| Income taxes expense | 1,175,023 | 2,064,212 | ||||||
| Net income | $ | 4,710,325 | $ | 7,031,529 | ||||
2
For the six months ended June 30, 2024 and 2023 (Unaudited)
Revenues
Revenues decreased by approximately $2.85 million, or approximately 5.9%, to $45.34 million for the six months ended June 30, 2024 from approximately $48.19 million for the six months ended June 30, 2023. The decrease was mainly due to a decline in demand for customer orders, which we attributed to the stalling recovery of China’s economy.
Cost of revenues
Cost of revenues primarily include cost of materials, direct labor costs, overhead, and other related incidental expenses that are directly attributable to the Company’s principal operations. Cost of revenues decreased by approximately $0.86 million, or approximately 2.8%, to $30.16 million for the six months ended June 30, 2024 from approximately $31.02 million for the six months ended June 30, 2023. The decrease was generally in line with decrease in revenue except some fixed cost such as lease expense and salary of administrative employees in production department.
Gross profit margin
The following table sets forth the overall gross profit margin of the Company:
For the Six Months Ended June 30, (Unaudited) | ||||||||
| 2024 | 2023 | |||||||
| Revenues | $ | 45,343,698 | $ | 48,190,076 | ||||
| Costs of revenues | 30,158,297 | 31,019,347 | ||||||
| Gross profit | $ | 15,185,401 | $ | 17,170,729 | ||||
| Gross profit margin % | 33.5 | % | 35.6 | % | ||||
Gross profit decreased by approximately $1.99 million, or approximately 11.6%, to $15.19 million for the six months ended June 30, 2024 from approximately $17.17 million for the six months ended June 30, 2023. Gross profit margin decreased from 35.6% for the six months ended June 30, 2023 to 33.5% for the six months ended June 30, 2024 as a result of certain fixed costs not decreasing proportionately with revenue.
Operating costs and expenses
Our operating costs and expenses consist of selling expenses, general and administrative expenses and research and development expenses.
Selling
The following table sets forth a breakdown of the selling expenses of the Company:
For the six months ended June 30, 2024 and 2023 (Unaudited)
| 2024 | 2023 | |||||||
| Transportation expenses | $ | 1,116,872 | $ | 1,137,936 | ||||
| Salaries and benefits | 663,298 | 698,086 | ||||||
| Entertainment expenses | 564,785 | 500,485 | ||||||
| Conference expenses | 505,530 | 493,850 | ||||||
| Travel allowance | 170,036 | 177,807 | ||||||
| Auto expenses | 139,266 | 118,629 | ||||||
| Advertising expenses | 859 | 8,275 | ||||||
| Other expenses | 38,892 | 26,002 | ||||||
| Total | $ | 3,199,538 | $ | 3,161,070 | ||||
3
The selling expenses increased by approximately $0.04 million, or approximately 1.22%, to $3.20 million for the six months ended June 30, 2024 from approximately $3.16 million for the six months ended June 30, 2023. The increase was mainly attributable to the combined effects of the followings:
| (a) | Our conference expenses increased by approximately $0.01 million, or approximately 2.37%, to $0.51 million for the six months ended June 30, 2024 from approximately $0.49 million for the six months ended June 30, 2023. Conference expenses are mainly related to the company’s market expansion, business development, business negotiation, medical expo, and exhibition affairs. These expenditures helped the Company promote its products, develop markets and channels, strengthen customer communication, and establish long-term and stable cooperative relations. |
| (b) | Our transportation expenses decreased by approximately $0.02 million, or approximately 1.85%, to $1.12 million for the six months ended June 30, 2024 from $1.14 million for the six months ended June 30, 2023. The reduction in business travel was due to a decline in demand for customer orders. |
| (c) | Our salary and benefits expenses decreased by approximately $0.03 million or approximately 4.98%, to approximately $0.66 million for the six months ended June 30, 2024 from approximately $0.70 million for the six months ended June 30, 2023. The decrease was due to a decrease in the salary and benefits of the sales team, which was in line with revenue decrease. |
| (d) | Our entertainment expenses amounted to approximately $0.56 million and $0.50 million for the six months ended June 30, 2024 and 2023, respectively. |
| (e) | Our auto expenses increased by approximately $0.02 million for the six months ended June 30, 2024. Other expenses mainly consisted of certification fees, depreciation expenses, express fees, communication fees and loading fees. |
General and administrative
General and administrative expenses primarily consisted of the following expenses:
For the six months ended June 30, 2024 and 2023 (Unaudited)
| 2024 | 2023 | |||||||
| Salaries and benefits | $ | 702,752 | $ | 738,077 | ||||
| Entertainment expenses | 651,888 | 606,820 | ||||||
| Conference fees | 460,998 | 374,022 | ||||||
| Auto expenses | 131,136 | 113,810 | ||||||
| Maintenance expenses | 50,006 | 50,199 | ||||||
| Depreciation expenses | 75,553 | 45,951 | ||||||
| Travel allowance | 68,024 | 72,283 | ||||||
| Office expenses | 36,737 | 45,664 | ||||||
| Surtax expenses | 303,891 | 302,376 | ||||||
| Amortization expenses | 19,177 | 19,696 | ||||||
| Rental expenses | 6,747 | 7,299 | ||||||
| Insurance expenses | 4,062 | 118,000 | ||||||
| Service expenses | 890,425 | 726,302 | ||||||
| Other expenses | 101,243 | 232,111 | ||||||
| Total | $ | 3,502,639 | $ | 3,452,610 | ||||
General and administrative expenses increased by approximately $0.05 million, or approximately 1.45%, to $3.50 million for the six months ended June 30, 2024, from approximately $3.45 million for the six months ended June 30, 2023. The increase was primarily due to (a) service expenses increasing by approximately $0.16 million from $0.73 million for the six months ended June 30, 2023 to $0.89 million for the six months ended June 30, 2024 due to the increasing in investment consulting fees, (b) insurance expenses decreasing by approximately $0.11 million or 96.56% from approximately $0.12 million for the six months ended June 30, 2023 to $4,062 for the six months ended June 30, 2024.
4
Research and development
The following table sets forth a breakdown of the research and development expenses of the Company:
For the six months ended June 30, 2024 and 2023 (Unaudited)
| 2024 | 2023 | |||||||
| Sample manufacturing expenses | $ | 691,328 | $ | 676,283 | ||||
| Salaries and benefits | 506,506 | 564,114 | ||||||
| Travel allowance | 69,751 | 58,886 | ||||||
| Depreciation expenses | 4,910 | 5,113 | ||||||
| Design expenses | 43,202 | 38,985 | ||||||
| Material expenses | 29,953 | 13,495 | ||||||
| Other expenses | 114,295 | 103,500 | ||||||
| Total | $ | 1,459,945 | $ | 1,460,376 | ||||
Research and development expenses stayed at approximately $1.46 million for the six months ended June 30, 2024 and 2023.
Income from operations
As a result of the factors described above, our income from operations decreased by approximately $3.20 million, or approximately 35.23%, to $5.89 million for the six months ended June 30, 2024 from approximately $9.10 million for the six months ended June 30, 2023.
Income tax expense
The provision for income taxes decreased by approximately $0.89 million, or approximately 43.1%, to $1.18 million for the six months ended June 30, 2024, from approximately $2.06 million for the six months ended June 30, 2023. The decrease was mainly due to the decrease of taxable income in 2024.
Net income
As a result of the factors described above, our net income decreased by approximately $2.32 million, or approximately 33.01%, to $4.71 million for the six months ended June 30, 2024 from approximately $7.03 million for the six months ended June 30, 2023.
Unrealized foreign currency translation adjustment
The Company’s reporting currency is the United States dollar (“US$”). The Company’s operations are primarily conducted through its PRC subsidiaries where the local currency is the functional currency. The functional currency of Kang Fu International Medical Co., Ltd., our Hong Kong subsidiary holding company, is the Hong Kong dollar and the functional currency of other operating subsidiaries is the Renminbi (“RMB”). Results of operations and cash flows are translated at average exchange rates during the period, assets and liabilities are translated at the unified exchange rate at the end of the period and equity is translated at historical exchange rates. Translation adjustments resulting from the process of translating the financial statements denominated in RMB into U.S. dollars are included in other comprehensive income. Our foreign currency translation loss for the six months ended June 30, 2024 and 2023 was approximately $3.52 million and $6.32 million, respectively. The change was primarily due to the exchange rate fluctuation of RMB against the U.S. dollar.
B. Liquidity and Capital Resources
Cash Flows and Working Capital
As of June 30, 2024 and as of December 31, 2023, we had cash of approximately $18.49 million and $16.93 million, respectively. We believe that our current cash, cash to be generated from our operations and access to capital market will be sufficient to meet our working capital needs for at least the next twelve months. We do not have any amounts committed to be provided by our related party. We are also not dependent upon future financing to meet our liquidity needs for the next twelve months. In order to implement our growth strategies, we plan to expand our business. With additional capacity, and varied product offerings, the Company will provide tailored “one-stop” services from wound care, to surgical auxiliary supplies, to disease prevention. To do so, we may need more capital through equity financing to expand our production and meet market demands.
5
Substantially all of our operations are conducted in China and all of our revenues, expense and cash are denominated in RMB. RMB is subject to the exchange control regulation in China, and, as a result, we may have difficulty in distributing any dividends outside of China due to PRC exchange control regulations which restrict the ability to convert RMB into U.S. Dollars.
Under applicable PRC regulations, foreign-invested enterprises in China may pay dividends only out of their accumulated profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, a foreign-invested enterprise in China is required to set aside at least 10% of its after-tax profit every year as its general reserves based on PRC accounting standards until the accumulative amount of such reserves reaches 50% of its registered capital. These reserves can’t be distributed as cash dividends. The board of directors of a foreign-invested enterprise has the discretion to allocate a portion of its after-tax profits to staff welfare and bonus funds, which can’t be distributed to equity owners except liquidation. Under PRC law, RMB can be converted into U.S. Dollars under the company’s “current account” (including dividends, trade and service-related foreign exchange transactions) rather than the “capital account” (including foreign direct investments and loans, without the prior approval of the SAFE).
For retained earnings accrued after such date, the Board will declare dividends after taking into account our operations, earnings, financial condition, the demand for cash and availability and other relevant factors. Any declaration, payment and amount of dividends, if any, should be subject to our By-laws, charter and applicable Chinese and U.S. state and federal laws and regulations, including the approval from the shareholders of each subsidiary which intends to declare such dividends, if applicable.
We have limited financial obligations dominated in U.S. dollars, thus the foreign currency restrictions and regulations in PRC on the dividends distribution will not have a material impact on the liquidity, financial condition and results of operations of our Company.
Cash Flow Summary
For the Six months Ended June 30, 2024 and 2023 (Unaudited)
| 2024 | 2023 | |||||||
| Net Cash Provided by (Used in) Operating Activities | $ | 1,015,799 | $ | (5,424,569 | ) | |||
| Net Cash Used in Investing Activities | (5,424,859 | ) | (3,866,151 | ) | ||||
| Net Cash Provided by Financing Activities | 6,134,401 | 721,677 | ||||||
| Effect of Exchange Rate Changes on Cash | (161,584 | ) | (306,443 | ) | ||||
| Cash at Beginning of Period | 16,926,878 | 26,736,700 | ||||||
| Cash at End of Period | $ | 18,490,635 | $ | 17,861,214 | ||||
For the Six months Ended June 30, 2024 and 2023 (Unaudited)
Cash Flow in Operating Activities
Net cash provided by operating activities was $1.0 million for the six months ended June 30, 2024, primarily comprised of net income of approximately $4.7 million and adjustment for non-cash items of approximately $1.3 million, decrease of bank acceptance receivable of approximately $1.4 million, increase of accounts payables of approximately $1.2 million, decrease in inventories of approximately $0.5 million, and increase of accrued expenses and other liabilities of approximately $0.2 million, offset by increase in accounts receivable of approximately $8.2 million.
Net cash used in operating activities was $5.4 million in the six months ended June 30, 2023, primarily comprised of net income of approximately $7.0 million and adjustment for non-cash items of approximately $0.5 million, increase in accounts receivable of approximately $14.1 million, decrease of bank acceptance receivable of approximately $2.8 million, decrease of accounts payable of approximately $1.6 million, increase in inventory of approximately $0.6 million.
6
Cash Flow in Investing Activities
Net cash used in investing activities was $5.4 million for the six months ended June 30, 2024. It consisted of purchases of property and equipment of approximately $0.01 million and advance to a related party of approximately $5.4 million.
Net cash used in investing activities was approximately $3.9 million for the six months ended June 30, 2023. It consisted of purchases of property and equipment of approximately $1.0 million, intangible assets of approximately $3.6 million, proceeds from disposal of fixed assets of approximately $0.4 million, and proceeds from disposal of long-term investment of approximately $0.4 million.
Cash Flow in Financing Activities
For the six months ended June 30, 2024, the Company had net cash provided by financing activities of approximately $6.1 million, which consisted of proceeds from convertible debt of approximately $5.6 million, proceeds from short-term bank loans of approximately $6.4 million and Repayment to short -term bank loans of approximately $5.8 million
For the six months ended June 30, 2023, the Company had net cash provided by financing activities of approximately $0.7 million, which consisted of the proceeds from short-term bank loans of approximately $5.3 million, and repayments of short-term bank loans of approximately $4.6 million
Off-Balance Sheet Arrangements
As of June 30, 2024 and December 31, 2023, there were no off-balance sheet arrangements.
C. Research and Development, Patents and Licenses, etc.
Please see Item 4. “Information on the Company—Business Overview—Intellectual Property” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2023, as filed with the SEC on April 24, 2024.
D. Trend Information
Other than as disclosed elsewhere in this unaudited condensed interim report, we are not aware of any trends, uncertainties, demands, commitments or events for the six months ended June 30, 2024 that are reasonably likely to have a material adverse effect on our net revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial conditions.
E. Critical Accounting Estimates
Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements. These financial statements are prepared in accordance with U.S. GAAP, which requires us to make estimates and assumptions that affect the reported amounts of our assets and liabilities and revenue and expenses, to disclose contingent assets and liabilities on the date of the consolidated financial statements, and to disclose the reported amounts of revenue and expenses incurred during the financial reporting period. The most significant estimates and assumptions include the collection of accounts receivable, the useful lives and impairment of our long-lived assets, and the provisions for income taxes. We continue to evaluate these estimates and assumptions that we believe to be reasonable under the circumstances. We rely on these evaluations as the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from those estimates. Some of our accounting policies require higher degrees of judgment than others in their application. We believe critical accounting policies as disclosed in this report reflect the more significant judgments and estimates used in preparation of our consolidated financial statements. We believe there have been no material changes to our critical accounting policies and estimates.
7
Use of Estimates
The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and related notes.
The most significant estimates and judgments include allowance for credit losses, the valuation of inventory, useful life of property, plant and equipment and income taxes related to realization of deferred tax assets and uncertain tax position. Actual amounts could differ from those estimates.
Accounts Receivable and Allowance for Credit Losses
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which requires the Company to measure and recognize expected credit losses for financial assets held and not accounted for at fair value through net income. The Company adopted this guidance effective January 1, 2020. ASC 326 introduces an approach based on expected losses to estimate the allowance for credit losses, which replaces the previous incurred loss impairment model. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. Accounts receivable are recognized and carried at the original invoiced amount less an estimated allowance for credit losses. The Company estimates the allowance for credit losses based on an analysis of the aging of accounts receivable, assessment of collectability, including any known or anticipated economic conditions, customer-specific circumstances, recent payment history and other relevant factors.
Inventories
Inventories are valued using the lower of cost or net realizable value. Cost is principally determined using the weighted-average method. Manufactured inventories included cost of materials, labor and overhead expenses. The Company records adjustments to inventory for excess quantities, obsolescence, or impairment, when appropriate, to reflect inventory at net realizable value. These adjustments are based upon a combination of factors including current sales volume, market conditions, lower of cost or market analysis and expected realizable value of the inventory.
8
Exhibit 99.3
Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results
YANGZHOU, China, September 20, 2024 -- Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today reported its unaudited financial results for the six months ended June 30, 2024. All amounts below are in U.S. dollars.
First Half 2024 Unaudited Financial Metrics:
| ● | Revenues was approximately $45.3 million for the six months ended June 30, 2024. |
| ● | Gross profit was approximately $15.2 million for the six months ended June 30, 2024. |
| ● | Gross margin was approximately 33.5% in the six months ended June 30, 2024. |
| ● | Income from operations was approximately $5.9 million for the six months ended June 30, 2024. |
| ● | Net income was approximately $4.7 million for the six months ended June 30, 2024. |
Mr. Yongjun Liu, Chairman of the Company, commented, “In the first half of 2024, we have been actively transitioning toward the high-end medical device industry, which is reflected in our financial results. Our total revenue for the first half of 2024 was $45.3 million, with a gross profit of $15.2 million and a gross margin of 33.5%. Given the overall economic slowdown during this period, we are pleased with these results. While these headwinds have impacted our short-term profit, they underscore the need to strengthen our operational resilience and focus on long-term sustainability. Currently, we are actively optimizing our product mix, increasing our focus on high-margin, high-quality consumables, and expanding our premium medical products portfolio. At the same time, we are reinforcing our upstream and downstream supply chains with the goal of achieving greater efficiency. The integration of AI capabilities not only drives innovation and operational improvements within our company but also enhances the products we deliver to business partners, positioning us to offer advanced, intelligent solutions across the market. In particular, our Speed Fox warehouse management and logistics platform was launched in May, and we participated in the world’s second-ever remote robotic lobectomy in July.”
“In addition, the construction of our integrated medical industrial park in Hainan is progressing well, and we expect it to further support our long-term growth objectives. We are confident this project, along with our other innovations and developments, will enhance our competitiveness and set a strong foundation for future financial performance.”
“In line with our confidence in the Company’s long-term prospects, we have initiated a $3 million share repurchase plan, reflecting our belief in the underlying value of our business. This decision underscores our commitment to creating shareholder value while maintaining a disciplined approach to capital allocation. Despite the short-term hurdles, we believe we are well-positioned to navigate this period of uncertainty and build sustainable growth in the coming quarters.”
First Half 2024 Unaudited Financial Results:
Revenues
Revenues decreased slightly by approximately $2.9 million, or 5.9% to approximately $45.3 million for the six months ended June 30, 2024, from approximately $48.2 million in the same period of fiscal year 2023. The decrease in revenues was primarily driven by a decline in demand for customer orders, which we attributed to the stalling recovery of China’s economy.
Cost of revenues
Cost of revenues primarily included the cost of materials, direct labor expenses, overhead, and other related incidental expenses that are directly attributable to the Company’s principal operations. Cost of revenues decreased by approximately $0.9 million, or 2.8%, to approximately $30.2 million for the six months ended June 30, 2024, from approximately $31.0 million in the same period of fiscal year 2023. The decrease was generally in line with the decrease in revenue except for certain fixed costs such as lease expense and salary of administrative employees in our production department.
Gross profit and margin
Gross profit decreased by approximately $2.0 million, or 11.6%, to approximately $15.2 million for the six months ended June 30, 2024, from approximately $17.2 million in the same period of fiscal year 2023. Gross profit margin was 33.5% for the six months ended June 30, 2024, compared to 35.6% for the six months ended June 30, 2023. This decline was primarily due to certain fixed costs not decreasing proportionately with revenue, while other factors remained largely unchanged.
Operating costs and expenses
Our operating costs and expenses consist of selling expenses, general and administrative expenses, and research and development expenses.
2
-Selling
Selling expenses increased by approximately $40,000, or 1.2%, to approximately $3.2 million for the six months ended June 30, 2024, from approximately $3.2 million in the same period of 2023. The increase in selling expenses was mainly due to the market business development expenses increased.
| 1) | Conference expenses increased by approximately $10,000, or approximately 2.4%, to $0.5 million for the six months ended June 30, 2024, from approximately $0.5 million for the six months ended June 30, 2023. Conference expenses are mainly related to the company’s market expansion, business development, business negotiation, medical expo, and exhibition affairs. These expenditures helped the Company promote its products, develop markets and channels, strengthen customer communication, and establish long-term and stable cooperative relations. |
| 2) | Transportation expenses decreased by approximately $20,000, or approximately 1.9%, to $1.1 million for the six months ended June 30, 2024, from $1.1 million for the six months ended June 30, 2023. The reduction in business travel was due to a decline in demand for customer orders. |
| 3) | Salary and benefits expenses decreased by approximately $30,000 or approximately 5.0%, to approximately $0.7 million for the six months ended June 30, 2024 from approximately $0.7 million for the six months ended June 30, 2023. The decrease was due to a decrease in the salary and benefits of the sales team, which was in line with revenue decrease. |
| 4) | Business development expenses amounted to approximately $0.6 million and $0.5 million for the six months ended June 30, 2024 and 2023, respectively. |
| 5) | Auto expenses increased by approximately $20,000 for the six months ended June 30, 2024. Other expenses mainly consisted of certification fees, depreciation expenses, express fees, communication fees and loading fees. |
-General and administrative expenses
General and administrative expenses increased by approximately $50,000, or 1.5%, to approximately $3.5 million for the six months ended June 30, 2024, from approximately $3.5 million in the same period of fiscal year 2023. The increase was primarily due to service expenses increasing by approximately $0.2 million from $0.7 million for the six months ended June 30, 2023 to $0.9 million for the six months ended June 30, 2024 due to an increase in investment consulting fees.
3
- Research and development expenses
Research and development expenses remained at $1.5 million for the six months ended June 30, 2024, as compared to the same period of fiscal year 2023.
Income from operations
Income from operations was approximately $5.9 million for the six months ended June 30, 2024.
Net income
Net income was approximately $4.7 million for the six months ended June 30, 2024, as a result of the factors described above.
Recent developments
On June 26, 2024, the board of directors (the “Board”) of the Company approved and authorized the Company’s proposal to adopt a share repurchase plan of up to $3 million of the Company’s outstanding ordinary shares (the “Share Repurchase Plan”). Under the Share Repurchase Plan, Company management is authorized to purchase ordinary shares from time to time through open market purchases or privately negotiated transactions at prevailing prices as permitted by securities laws and other legal requirements, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company’s insider trading policy, and subject to market conditions and other factors.
About Meihua International Medical Technologies Co., Ltd.
Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under Meihua’s own brands and are also sourced and distributed from other manufacturers. The Company has received an international “CE” certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 800 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.
4
For more information, please visit www.meihuamed.com.
Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, and its ability to fully execute on the planned agreement, the Company’s future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, including under the section entitled “Risk Factors” in its annual report on Form 20-F, as well as on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
IR Department
Email: secretary@meihuamed.com
Tel: +86-0514-89800199
Christensen
Yang Song
Email: yang.song@christensencomms.com
Tel: +86-010-59001548
5